Use of Antiarrhythmic Drugs in Pediatrics

May 3, 2021 updated by: Areej Tarek Mostafa mohamed makhlouf, Assiut University

Adescriptive Study on the Use of Antiarrhythmic Drugs in Pediatrics Cardiology Unit Assiut University

This study aims to describe the use of Cardiovascular Drugs in Pediatrics Cardiology unit Assiut University. As regard :

  • indications of use .
  • proper dosage.
  • proper management of side effects of their use.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Arrhythmias occur in children and adolescents with congenital heart disease as well as those with structurally normal hearts. Antiarrhythmic medications primarily affect the ion channels in cardiac myocytes that are responsible for generating currents that create the action potential.

By altering the activity of these ion channels, the action potential is changed in an attempt to reduce the likelihood of sustained arrhythmias. There is awide range of antiarrhysmic drugs used in treatment Antiarrhysmics are therefore divided into five classes

Class I: Antiarrhythmics that affect sodium channels (slow depolarization) Class II: Drugs that counteract the sympathetic nervous system, predominantly beta-blockers Class III: drugs that affect the potasium channels ( prolong repolarization) Class IV: Drugs that affect calcium channels (Calcium channel blockers) Class V: Vagotonic drugs (Digoxin) and other miscellaneous drugs

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 16 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

1- Patients' selection:- patients from 1 month age till 18 years on antiarrhythmic medications in Cardiology Unit Assiut University Hospital antiarrhytmic medications .

Description

Inclusion Criteria:

  • All Patients with Arrhythmic cardiac diseases admitted at cardiology unit Assiut University Hospital aged from 1 month to 18 years

Exclusion Criteria:

  • ● Patients with diseases rather than arrhythmic cardiac diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
descripe the use of antiarrhythmic drugs in pediatrics
Time Frame: one year

to asses the use of antiarrhythmic drugs in cardiology unit whether its used for proper indications matching with last guidelines or not to asses also dosage (gram per Kg of weight) of each drug used .and detrimine the side effects appear and its proper management.

  • proper dosage.
  • proper management of side effects of their use
one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

October 1, 2021

Primary Completion (Anticipated)

April 1, 2022

Study Completion (Anticipated)

October 1, 2022

Study Registration Dates

First Submitted

April 14, 2021

First Submitted That Met QC Criteria

April 24, 2021

First Posted (Actual)

April 28, 2021

Study Record Updates

Last Update Posted (Actual)

May 6, 2021

Last Update Submitted That Met QC Criteria

May 3, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • antiarrhythmic drugs in pediat

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Antiarrhythmic Toxicity

Clinical Trials on Antiarrhythmic drug

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe